Global X S&P Biotech ETF (ASX:CURE)
Australia
· Delayed Price · Currency is AUD 42.49
+0.31 (0.73%)
Apr 24, 2025, 2:10 PM AEST
-4.69% (1Y)
| Assets | 28.22M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -5.38% |
| Volume | 182 |
| Open | 42.28 |
| Previous Close | 42.18 |
| Day's Range | 42.28 - 42.49 |
| 52-Week Low | 38.76 |
| 52-Week High | 54.72 |
| Beta | 0.90 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of -5.38% in the past year, including dividends. Since the fund's inception, the average annual return has been 0.83%.
Top 10 Holdings
25.48% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 2.70% |
| Vertex Pharmaceuticals Incorporated | VRTX | 2.67% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.64% |
| Insmed Incorporated | INSM | 2.60% |
| United Therapeutics Corporation | UTHR | 2.58% |
| Exact Sciences Corporation | EXAS | 2.57% |
| Neurocrine Biosciences, Inc. | NBIX | 2.52% |
| Gilead Sciences, Inc. | GILD | 2.50% |
| Amgen Inc. | AMGN | 2.41% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.29% |